One-Minute Summary

Key Conclusions:

  • Multiple 2024–2025 systematic reviews confirm PRP (Platelet-Rich Plasma — concentrate of your own blood platelets rich in growth factors) significantly outperforms HA (hyaluronic acid — sugar molecule naturally in skin/joint, holds water), with the difference still visible at 6–12 months. Against placebo, a 2025 meta-analysis (11 randomized controlled trials, 1,616 patients) found PRP better at 3 and 6 months but no difference at 12 months (Auroux 2025).
  • 2025 Network Meta-Analysis (NMA — indirect multi-treatment comparison) of one, two, and three PRP injections: three injections (PRP3) yield the best VAS (Visual Analog Scale — 0–10 line scale for pain rating) pain and WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index — knee/hip OA pain & function scale) function improvement.
  • Leukocyte concentration mainly affects side effects, not efficacy: a 2026 network meta-analysis (21 randomized controlled trials, 2,254 patients) found no statistically significant efficacy difference in the direct comparison of LP-PRP (Leukocyte-Poor PRP — PRP filtered to remove white blood cells, gentler inflammation) and LR-PRP (Leukocyte-Rich PRP) (Xu 2026). Leukocyte-rich PRP more often causes brief post-injection soreness and swelling, while leukocyte-poor PRP has a side-effect profile similar to HA (Nakagawa 2026).
  • Clinical recommendation: Kellgren-Lawrence (KL) (OA X-ray severity grade 0–4) II–III patients respond best; KL IV severe disease shows limited response.
  • PRP serves well as a surgery-deferral strategy — highly valuable for middle-aged patients reluctant or not yet ready for knee replacement.

The Knee OA Treatment Ladder

Osteoarthritis (OA — wear-and-tear joint disease) treatment generally follows a stepwise approach by severity:

StageKL GradeStandard TreatmentPRP Role
EarlyI–IIWeight management, rehab, oral NSAIDsPreventive intervention, delay degeneration
MidII–III+ HA, corticosteroid injectionFirst-choice adjunct, outperforms HA
LateIII–IVConsider knee replacementDefer surgery, symptom relief
End-stageIVKnee replacement primaryLimited response; consider post-op adjunct
Swipe sideways to view the full table

Why PRP Has a Theoretical Basis for OA

OA pathology is not just "cartilage wear" — it is whole-joint microenvironment inflammation and imbalance:

  • Synovitis
  • Cartilage matrix degradation
  • Subchondral bone remodeling
  • Synovial fluid biochemical abnormality

PRP releases high-concentration growth factors targeting these mechanisms:

  • TGF-β (Transforming Growth Factor Beta — fibrosis & repair signal): chondrocyte proliferation, suppression of IL-1β (Interleukin-1 beta / Interleukin-6) inflammation
  • PDGF (Platelet-Derived Growth Factor — platelet-released cell growth signal): stimulates extracellular matrix synthesis
  • IGF-1 (Insulin-like Growth Factor 1 — growth/repair signal molecule): promotes type II collagen synthesis
  • VEGF (Vascular Endothelial Growth Factor — new blood vessel signal): improves subchondral bone perfusion

2024–2025 Latest Evidence

Major Systematic Reviews

A 2024 Annals of Medicine and Surgery comparative effectiveness review of intra-articular treatments concluded:

PRP outperformed all comparators (HA, corticosteroid, placebo) on three key indicators: success rate, achievement of minimal clinically important difference (MCID — smallest treatment improvement patient notices), and rates of avoiding re-intervention.

Statistical Significance

The 2025 PLOS One meta-analysis actually compared PRP combined with HA against PRP alone, not PRP against HA:

  • Adverse events: lower risk with the combination than with PRP alone (OR 0.54, 95% CI 0.33–0.85)
  • For PRP versus HA head to head, rely on the systematic reviews in the previous section

Number of Injections and Effect

The 2025 Network Meta-Analysis compared the number of injections: one (PRP1), two (PRP2), and three (PRP3). Three injections continued to show the best efficacy. It compared injection counts, not concentration multiples; how platelet concentration affects outcome is a separate question addressed by other studies.

Key insight: "PRP works for everyone" oversimplifies. Platelet concentration and number of injections both significantly affect clinical outcome; leukocyte ratio mainly affects short-term post-injection soreness.


Best Responders

Strong Candidates

  1. KL II–III (moderate) — substantive cartilage to preserve
  2. Pain affecting daily activity but not yet disabling
  3. Not suitable or unwilling for joint replacement
  4. Limited or diminishing HA response
  5. Age 45–65, high activity demand

Poor-Response Scenarios

  • KL IV severe (cartilage nearly absent)
  • Severe obesity (BMI >35) — mechanical stress overrides biological effect
  • Mainly mechanical symptoms (locking, catching) — may need surgery
  • Strong inflammatory arthritis (rheumatoid, etc.) — primary disease must be addressed

Protocol Design: Frequency and Intervals

Common protocols:

Three-Shot Protocol

  • Standard 3 sessions, about 1–2 weeks apart (adjusted to response at follow-up)
  • Most common; the basis of most studies
  • Peak effect at month 6

Single-Dose Intensified

  • A single higher-concentration injection
  • Effective in select KL II–III patients
  • Re-evaluate at 6 months for additional dose

Maintenance

  • Initial 3-shot then booster every 6–12 months
  • Suits long-term management plans

PRP + HA Combination: 1 + 1 > 2?

See related article on PRP + HA combined knee strategy.

Briefly:

  • PRP + HA outperforms HA alone (high evidence)
  • PRP + HA vs PRP alone: evidence mixed; some studies favor combination especially after 6–12 months
  • Clinical practice: many physicians use "PRP first, then HA at 4–6 weeks" sequential strategy

Side Effects and Risks

Autologous-blood PRP has high safety:

Common:

  • 24–72 hour post-injection joint swelling and pain (initial growth-factor inflammation)
  • Transient activity restriction

Rare:

  • Infection (with sterile technique <0.1%)
  • Brief symptom worsening

Contraindications:

  • Active infection
  • Severe anemia (Hb <10 g/dL)
  • Platelet function disorders
  • Antiplatelet medication (consult primary physician)
  • Uncontrolled malignancy

PRP Quality: Critical to Outcomes

Not all "PRP" is equal. Verify:

  1. Centrifugation system: standardized, reproducible closed system?
  2. Platelet concentration measurement: validated each session?
  3. Leukocyte ratio: leukocyte-poor and leukocyte-rich PRP work about equally well; leukocyte-poor causes less short-term soreness and swelling, so the choice is discussed with your doctor case by case
  4. Freshness: blood draw to injection within 30–60 minutes
  5. Injection site: ultrasound-guided beats blind injection

Key insight: Many "PRP failures" are preparation or injection-technique problems, not PRP ineffectiveness. Choosing a clinic with full process standardization is essential.


When to Consider Knee Replacement

PRP is not a panacea. These should prompt orthopedic surgical consultation:

  • Strict conservative care for 6–12 months still leaves severe pain affecting life
  • KL IV severe degeneration
  • Mechanical locking, deformity
  • Recurrent joint effusion

PRP's role is to defer or avoid surgery — not replace surgery when truly needed.


Common questions

Does PRP actually work for knee osteoarthritis, and is it really better than hyaluronic acid?

Looking at the systematic reviews from the last couple of years, PRP does tend to improve pain and function more than hyaluronic acid. Compared with placebo, the difference shows up mainly at three to six months after treatment and is hard to see by twelve months. That said, it doesn't work the same for everyone — platelet concentration, how many injections you get, and the leukocyte ratio all shift the result, so it really comes down to your individual situation.

Is my level of knee degeneration suitable for PRP?

The people who tend to respond well are KL grade II–III, moderate degeneration where there's still real cartilage to preserve, usually around 45 to 65 with an active lifestyle. If the cartilage is nearly gone at KL IV, or if there's severe obesity or mainly mechanical problems like locking and catching, the effect tends to be limited, and that's something we'd want to assess in person before deciding.

How many PRP injections do I need, and when will I feel the effect?

Our standard is three injections about 1 to 2 weeks apart, with the spacing adjusted to how you respond at follow-up; most studies also use a three-dose design, with the effect usually peaking around month 6. Some moderate-degeneration patients go with a single higher-concentration dose and then reassess at six months. If you want to hold the result longer, a booster every 6 to 12 months is an option.

Is PRP safe, and what should I expect afterwards?

PRP is prepared from your own blood, so the safety profile is good. The common thing is joint swelling and soreness in the first 24 to 72 hours — that's the early growth-factor inflammation, it settles over a few days, and you'll have some limited movement during that time. Infection is uncommon, under 0.1% with sterile technique. If you have an active infection, severe anemia, or you're on antiplatelet medication, we'd talk that through first.

If I get PRP, does that mean I won't need a knee replacement?

It's not quite that. PRP's role is more about deferring surgery or helping you avoid getting to that point — it isn't a substitute for surgery when surgery is genuinely needed. If you've done six to twelve months of conservative care and still have severe pain affecting daily life, or you're already at KL IV with clear deformity, that's when you'd sit down with an orthopedic surgeon to discuss the surgical options.

How do PRP, hyaluronic acid and corticosteroid injections differ, and how do I choose?

They act at different levels; they are not three strengths of the same thing. PRP relies on the body's own repair response, which needs time to play out, so it is usually given in several sessions with gaps between them. PRP and hyaluronic acid are often combined, while corticosteroid is usually not scheduled at the same time as PRP and needs to be spaced apart. The full comparison is in PRP, hyaluronic acid or corticosteroid joint injection; which one fits depends on your joint.

How are the number of injections and the spacing actually planned?

Our standard course is three injections about one to two weeks apart, which sits inside the range the 2024 ESSKA-ORBIT consensus recommends (two to four injections, one to three weeks apart; PMID: 38436492). Once the dates are set, the spacing is still adjusted to how you respond at each visit. Assessment, scheduling and follow-up are covered in planning a joint injection course.

I'm not sure which stage my knee is at, or whether I should see a doctor. What now?

Start with the stages of knee osteoarthritis, K-L grading and what to do at each; for timing, see when joint pain needs a doctor. The stage itself has to be set from an X-ray and an in-person assessment.


Conclusion: PRP Is the "Mid-Stage Weapon" for Knee OA

For moderate degeneration with active patients, PRP has progressed from "experimental therapy" 5 years ago to "mainstream non-surgical option" in 2026. The latest evidence clearly shows:

  • Overall superiority to HA
  • Three injections do better; leukocyte-poor and leukocyte-rich work about equally well, with less short-term soreness from leukocyte-poor
  • Excellent surgery-deferral strategy

But PRP is not a miracle, nor for everyone. Professional evaluation, realistic expectations, and standardized preparation are the three success factors.

For evaluation of knee PRP suitability, see our joint injection regenerative service or book a consultation.


Medical References

  1. Comparative effectiveness of intra-articular therapies in knee OA. Annals of Medicine and Surgery. 2024.
  2. Efficacy and safety of intra-articular PRP versus sodium hyaluronate. PLOS One. 2025. PMID: 40117278.
  3. Comparative efficacy of different doses of PRP for knee OA: network meta-analysis. PubMed PMID (PubMed Identifier): 40022138. 2025.
  4. Comprehensive Summary of Meta-Analyses on PRP for Knee OA. Military Medicine. 2024.
  5. PRP Injections for Knee OA: Influence of Platelet Concentration: Meta-analysis. Bensa A, et al. 2025.
  6. Corticosteroids, HA, PRP, and Cell-Based Therapies for Knee OA: Systematic Review. 2025.
  7. Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis. Xu B, et al. J Orthop Surg Res. 2026. PMID: 41629990.
  8. Assessment of adverse events and safety associated with intra-articular platelet-rich plasma injections compared to other injectates for knee osteoarthritis: A systematic review and meta-analysis. Nakagawa HF, et al. PM R. 2026. PMID: 42101047.
  9. Efficacy of intra-articular platelet-rich plasma compared with placebo in knee osteoarthritis: A systematic review and meta-analysis. Auroux M, et al. Joint Bone Spine. 2025. PMID: 40653151.

Editorial review: Reviewed by Dr. Ta-Ju Liu. Last reviewed 2026-04-27.